WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal Homepage: www.ijrpr.com ISSN 2582-7421

Emerging Frontiers in Oncology: Advances in Novel Cancer Therapeutics

Sushrith Srinath Puttur

Srinivas College of Pharmacy, Mangalore, Karnataka
Email Id: sushrithsp402@gmail.com

DOI : https://doi.org/10.55248/gengpi.07.1026.34037

ABSTRACT

Despite steady progress in early detection and treatment, cancer remains a severe global health crisis. Indeed, both incidence and mortality rates continue to climb. Standard options like surgery, chemotherapy, and radiation therapy still serve as the foundation of patient care. However, systemic toxicity, poor target specificity, and drug resistance frequently compromise their success. They are simply not enough. Recently, the development of novel therapies targeting precise molecular and immunological pathways has accelerated. These innovations span immunotherapy, gene therapy, nanomedicine, targeted agents, and precision oncology. Their shared goal is simple: maximize patient survival while minimizing debilitating side effects. This review evaluates key oncology developments emerging since 2023. We examine how these therapies function, their clinical utility, current roadblocks, and future outlooks. Ultimately, combining multidisciplinary strategies with cutting-edge technology will likely reshape oncology, paving the way for highly individualized and effective patient care.

Keywords: Cancer Therapeutics, Immunotherapy, Targeted Therapy, Nanomedicine, Gene Therapy, Precision Oncology

INTRODUCTION

Cancer ranks among the most severe global health threats, claiming millions of lives annually and straining clinical resources worldwide. Traditional approaches like chemotherapy, radiation, and surgery have long served as the frontline defence. However, they lack precision. Because these therapies target all fast-dividing cells, healthy tissues suffer immense collateral damage [1,2].

Recent breakthroughs in molecular biology have changed this landscape. By mapping tumour genomics, researchers can now pinpoint the exact pathways driving cancer growth. This knowledge has accelerated the development of targeted therapies and immunotherapies, which offer greater precision and fewer side effects [3,4]. Immunotherapy, in particular, has reshaped modern oncology. It trains the patient's own immune system to identify and destroy cancer cells, yielding long-lasting recovery in several patient populations [5].

At the same time, cutting-edge tools are reshaping patient care. Gene editing, nanotech-based drug delivery, and AI-powered precision medicine allow clinicians to design highly individualized treatment plans [6-8]. This clinical personalization improves patient outcomes while sparing them from ineffective treatments. Yet, major obstacles persist. Drug resistance, tumour evolution, prohibitive costs, and unequal access to care continue to obstruct progress [9,10]. Addressing these barriers requires a unified effort to discover and adopt next-generation therapies.

This review examines modern oncology's emerging treatments. We analyse their underlying mechanisms, clinical utility, current roadblocks, and future directions.

METHODOLOGY

A systematic literature review was conducted using electronic databases including PubMed, Scopus, Web of Science, and ScienceDirect to identify relevant studies published between January 2023 and March 2026. Search terms included “cancer therapeutics,” “immunotherapy,” “targeted therapy,” “gene therapy,” “nanomedicine,” and “precision oncology,” combined using Boolean operators.

Inclusion criteria comprised peer-reviewed original research articles, systematic reviews, and clinical trials focusing on novel cancer therapies. Articles published prior to 2023, non-English publications, and studies lacking methodological rigor were excluded. Data were extracted and synthesized qualitatively, with emphasis on therapeutic mechanisms, clinical efficacy, and safety profiles. Preference was given to high-quality evidence such as randomized controlled trials and systematic reviews [1,2]

TRADITIONAL CANCER TREATMENTS: AN OVERVIEW

Standard clinical oncology still relies heavily on conventional cancer therapies, especially when managing localized or early-stage malignancies. For solid tumors, surgical resection represents the primary line of defence. It can cure the patient if the surgeon achieves complete tumor removal. But metastasis changes everything. Once the disease spreads, surgery's effectiveness drops sharply [11]. Chemotherapy relies on cytotoxic agents. These drugs aggressively attack rapidly dividing cells. Although they successfully shrink tumor mass, patients pay a heavy price. Systemic toxicities like myelosuppression, gastrointestinal distress, and hair loss remain major challenges [12,13].

Radiotherapy damages cancer cell DNA using ionizing radiation, leading to cell death. Modern techniques like intensity-modulated radiotherapy (IMRT) offer better precision. Even so, protecting healthy tissue from radiation damage is an ongoing struggle [14,15]. These standard options are widely used. Yet, they face steep hurdles. Tumors are heterogeneous, adapt quickly to build resistance, and these therapies lack specificity. Consequently, researchers must design more targeted options [16,17].

TARGETED THERAPY

By selectively disrupting the molecular pathways that fuel tumor development, targeted therapy has redefined modern cancer treatment. It works on specific biological markers. These include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and tyrosine kinases. Clinicians primarily use monoclonal antibodies and small-molecule inhibitors to achieve this selective inhibition [18–20]. The clinical benefits are clear. Solid therapeutic results have been documented in breast, colorectal, and non-small cell lung cancers [21]. However, tumors often adapt. Resistance mechanisms—frequently driven by genetic mutations and pathway redundancy—can degrade treatment durability over time [22].

The field must evolve. Designing bispecific antibodies and antibody-drug conjugates will be essential to improve targeting accuracy and overcome therapy evasion [23,24].

IMMUNOTHERAPY

By training the body's immune system to identify and eliminate malignant cells, immunotherapy has fundamentally transformed oncology. It works. Clinicians have seen outstanding results across various cancer types using immune checkpoint inhibitors that target the PD-1, PD-L1, and CTLA-4 pathways [25,26]. Similarly, hematological malignancies have responded remarkably well to chimeric antigen receptor T-cell (CAR-T) therapy [27]. To boost anti-tumor immune activity, researchers also utilize cancer vaccines and cytokine therapies. However, these approaches still face hurdles regarding patient toxicity and inconsistent efficacy [28,29]. Newer methods, including bispecific T-cell engagers and tumor-infiltrating lymphocytes, are currently undergoing clinical evaluation [30]. Yet, challenges persist. Immunotherapy often triggers immune-related side effects, and patient response rates remain highly unpredictable [31].

ONCOLOGICAL GENE THERAPY

Correcting or wiping out malignant cells through genetic modification introduces a powerful paradigm for cancer care. Several tools make this possible. Specifically, scientists employ gene replacement, gene silencing, and CRISPR-Cas9 genome editing [32,33]. Another avenue involves oncolytic viruses, which infect tumor cells to trigger their destruction and awaken the immune system [34]. This approach holds immense promise. However, widespread clinical use hinges on solving major problems like delivery vehicle efficiency, off-target activity, and ethical concerns [35,36].

NANOMEDICINE AND DRUG DELIVERY SYSTEMS

Cancer therapy is significantly improved by nanomedicine, which refines how drugs are delivered while minimizing overall toxicity to the body. Using liposomes, dendrimers, and polymeric carriers, nanoparticles facilitate targeted delivery via both active and passive pathways [37–41]. Tumour tissues accumulate these particles naturally through the enhanced permeability and retention (EPR) effect [42]. Many nano formulations have already cleared clinical hurdles. They show better pharmacokinetics and fewer side effects. Even so, challenges persist. Issues like toxicity, manufacturing scalability, and complex regulatory pathways must still be addressed [43,44].

PRECISION ONCOLOGY

By analysing genomic and molecular profiles, precision oncology customizes cancer therapy for the individual. Actionable mutations are identified through next-generation sequencing, while appropriate therapies are selected using specific biomarkers [45,46]. Data interpretation is now driven by artificial intelligence, which streamlines clinical decisions [47,48]. Real-time monitoring is possible. Modern approaches like liquid biopsy and multi-omics integration allow physicians to adjust treatments on the fly [49]. Still, hurdles exist. Implementation remains both expensive and operationally complex [50].

COMBINATION THERAPIES

Integrating various treatment methods allows clinicians to boost therapeutic impact while simultaneously addressing treatment resistance. Approaches frequently involve pairing immunotherapy alongside radiotherapy, chemotherapy, or precision-targeted treatments [51–53]. By attacking multiple pathways at once, dual-targeting methods often yield superior patient outcomes [54]. Despite these gains, clinicians must account for elevated toxicity levels, complex drug interactions, and substantial financial burdens [55,56].

CURRENT BARRIERS

Modern oncology faces a series of complex difficulties that remain unsolved. Primary concerns are tumour diversity and the development of therapeutic resistance. Patients often face severe treatment toxicities, while systemic issues like high expenses and lack of availability hinder care delivery. There is also a notable lag in turning research breakthroughs into real-world medicine, compounded by ongoing regulatory and ethical debates. A concerted, multi-field effort is vital to closing these gaps [57–62].

FUTURE OUTLOOK

Oncology is shifting toward high-tech modalities like bispecific antibodies, mRNA platforms, and antibody-drug conjugates [63]. By incorporating machine learning, clinicians can achieve greater precision in diagnosis and strategy [64]. Advances in multi-omics will eventually unlock bespoke therapy designs, complemented by nanotechnology that enhances drug delivery precision [65–67]. Ultimately, the trajectory of cancer care hinges on solving logistical hurdles and ensuring these advancements reach patients in need [68].

CONCLUSION

Modern oncology has pivoted away from conventional models toward more sophisticated therapeutic strategies. By incorporating immunotherapy, precision medicine, and gene therapy, the medical community has boosted efficacy and patient outcomes significantly. Despite such progress, researchers must still contend with persistent barriers, specifically regarding treatment toxicity, financial accessibility, and biological resistance. Future success relies on consistent research and the application of emerging technologies to bridge these gaps. In essence, these developments mark a definitive shift toward precision-based care, bringing renewed optimism for patient survival and long-term health [69,70].

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

2. Behrens C, Griesinger F. Challenges of conventional cancer therapies and opportunities for precision medicine. Nat Rev Clin Oncol. 2023;20(12):745–60.

3. Liu B, Zhou H, Tan L, Siu KTH, Wang H, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024; 9:175.

4. Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 2024; 9:201.

5. Chen DS, Mellman I. Next-generation cancer immunotherapy. Nature. 2024;629(8013):37–49.

6. Gladstone BP, Beha J, Hakariya A, Missios P, Malek NP, Bitzer M, et al. Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. npj Precis Oncol. 2025; 9:96.

7. Zhuang L, Park SH, Skates SJ, Prosper AE, Aberle DR, Hsu W. Advancing precision oncology through modeling of longitudinal and multimodal data. arXiv. 2025;2502.07836.

8. Sadanandan B, Behzadan V. Promise of data-driven modeling and decision support for precision oncology and theranostics. arXiv. 2025;2505.09899.

9. Wang M, Chen S, He X, Yuan Y, Wei X. Targeting inflammation as cancer therapy. J Hematol Oncol. 2024; 17:13.

10. Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024;21(5):312–29.

11. Cloyd JM, Norton JA. Advances in surgical oncology in the era of precision medicine. Lancet Oncol. 2023;24(11): e517–27.

12. Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024; 9:92.

13. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2024;24(2):89–106.

14. Citrin DE. Recent developments in radiotherapy. N Engl J Med. 2024;390(7):645–57.

15. Baumann M, Krause M. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2023;23(9):541–58.

16. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2023;20(1):7–20.

17. Nussinov R, Tsai CJ, Jang H. Precision medicine and targeted cancer therapies. Nat Rev Drug Discov. 2024;23(4):255–76.

18. Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024; 12:16.

19. Zhang P, Yue L, Leng Q, Chang C, Gan C, Ye T, et al. Targeting FGFR for cancer therapy. J Hematol Oncol. 2024; 17:39.

20. Xue Y, Ruan Y, Wang Y, Xiao P, Xu J. Signaling pathways in liver cancer: pathogenesis and targeted therapy. Mol Biomed. 2024; 5:20.

21. Subbiah V, Kurzrock R. Universal genomic testing in oncology: clinical applications of targeted therapies. J Clin Oncol. 2024;42(8):865–78.

22. Hanker AB, Sudhan DR, Arteaga CL. Overcoming therapeutic resistance in cancer. Cancer Cell. 2024;42(1):14–31.

23. Bogen JP, Carrasco-Triguero M, Ramakrishnan V. Antibody-drug conjugates in oncology: current status and future directions. Nat Rev Drug Discov. 2024;23(8):603–26.

24. Ellerman D. Bispecific T-cell engagers in oncology. Nat Rev Drug Discov. 2023;22(7):537–54.

25. Zhao Y, Zhang Y, Wang X, Li Q, Chen L. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct Target Ther. 2024; 9:130.

26. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and emerging immune checkpoints in cancer immunotherapy. Nat Rev Immunol. 2024;24(2):101–18.

27. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2024;390(4):357–69.

28. Sahin U, Türeci Ö. Personalized mRNA cancer vaccines. Nat Rev Drug Discov. 2024;23(1):15–34.

29. Waldmann TA. Cytokines in cancer immunotherapy. Nat Rev Immunol. 2023;23(8):502–17.

30. Rosenberg SA, Restifo NP. Cell transfer immunotherapy and tumor-infiltrating lymphocytes. Science. 2024;383(6683): eadj4973.

31. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2024;390(9):814–27.

32. Mullard A. Gene-editing therapies advance in oncology. Nat Rev Drug Discov. 2024;23(5):327–29.

33. Doudna JA. CRISPR-based therapeutics: progress and prospects. Science. 2024;384(6697): eadm8184.

34. Russell SJ, Barber GN. Oncolytic viruses as anticancer therapeutics. Nat Biotechnol. 2024;42(2):169–81.

35. Stadtmauer EA, Fraietta JA, Davis MM. Clinical applications of gene therapy in cancer. J Clin Oncol. 2025;43(4):321–34.

36. Musunuru K, High KA. Ethical considerations in human genome editing. N Engl J Med. 2024;390(12):1125–32.

37. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2024;24(3):187–205.

38. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2023; 357:1–12.

39. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2024;23(4):279–300.

40. Kesharwani P, Iyer AK. Dendrimer-based nanomedicine for cancer therapy. Prog Polym Sci. 2024; 145:101735.

41. Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16(1): e1869.

42. Shi Y, van der Meel R, Theek B, Oude Blenke E, Pieters EH, Fens MHAM, et al. The EPR effect and beyond: strategies to improve tumor targeting. Nat Rev Mater. 2023;8(3):187–204.

43. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development. Nat Rev Drug Discov. 2024;23(2):94–115.

44. Park K. The drug delivery field at the inflection point. J Control Release. 2023; 360:404–10.

45. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision oncology. Genome Med. 2024; 16:21.

46. Marquart J, Chen EY, Prasad V. Estimation of the percentage of patients who benefit from genome-driven oncology. JAMA Oncol. 2024;10(2):188–94.

47. Chakravarty D, Solit DB. Clinical cancer genomics and personalized oncology. Nat Rev Genet. 2024;25(1):45–61.

48. Abdeldjouad FZ, Brahami M, Sabri M. Evaluating the effectiveness of artificial intelligence in predicting adverse drug reactions among cancer patients: a systematic review and meta-analysis. arXiv. 2024;2404.05762.

49. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2024;25(3):205–22.

50. Mody K, Kasi PM, Yang JD. Implementation challenges in precision oncology. Cancers (Basel). 2025;17(5):821.

51. Emens LA. Chemoimmunotherapy combinations in cancer treatment. Cancer J. 2024;30(1):12–21.

52. Paz-Ares L, O'Brien MER, Mauer M. Combination immunotherapy strategies in lung cancer. Lancet. 2024;403(10428):932–45.

53. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2024;57(2):231–48.

54. Flaherty KT, Infante JR, Daud A. Combined BRAF and MEK inhibition in melanoma: updated perspectives. N Engl J Med. 2024;390(6):541–53.

55. Schöffski P, Brown J. Toxicity management in combination cancer therapy. Ann Oncol. 2024;35(4):311–24.

56. Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A. 2024;121(9): e2319874121.

57. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2024;626(7998):36–47.

58. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution. Cell. 2024;187(1):22–39.

59. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D. Cardiotoxicity of anticancer treatments. Lancet Oncol. 2024;25(2):e78–91.

60. Aggarwal A, Nossiter J, Cathcart P, van der Meulen J. Financial toxicity in cancer care. Nat Rev Clin Oncol. 2024;21(3):139–50.

61. Baylis F, Darnovsky M. Ethics of genome editing in oncology. Lancet Oncol. 2024;25(5): e234–42.

62. Seymour LK, Ivy SP, Sargent D, Spriggs DR, Baker LH, Rubinstein L, et al. The design of phase I–III clinical trials in precision oncology. Nat Rev Clin Oncol. 2024;21(6):379–94.

63. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for next-generation antibody-drug conjugates. Nat Rev Drug Discov. 2024;23(6):437–59.

64. Topol EJ. Artificial intelligence in oncology and medicine. Nat Med. 2024;30(1):14–26.

65. Riedl JM, Posch F, Prager GW. Precision oncology: current landscape, emerging trends, challenges, and future perspectives. Cells. 2025;14(22):1804.

66. Zhao Y, Adjei AA. Biomarker-driven combination therapies in oncology. Nat Rev Clin Oncol. 2024;21(8):493–509.

67. Mitchell MJ, King MR. Smart nanomaterials for cancer theranostics. Nat Rev Mater. 2024;9(4):287–304.

68. Zafar SY, Abernethy AP. Future directions in cancer care delivery and accessibility. J Clin Oncol. 2025;43(2):101–9.

69. Nussinov R, Jang H, Tsai CJ. Precision oncology: from molecular mechanisms to clinical applications. Trends Cancer. 2025;11(2):89–104.

70. Liu B, Zhou H, Tan L, Siu KTH, Wang H, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024; 9:175.